A question of great importance is how to decide what a public health system must pay. Every day, the adoption of Health Technology Assessments (HTA) to define what should or should not be reimbursed by public health systems becomes more common internationally. Among the variables analyzed by HTA, one stands out in several countries where it is practiced: the cost-effectiveness.
However, the limits of this type of evaluation are becoming increasingly clear, especially in the case of rare diseases. The international literature has revealed that the likelihood of an orphan drug to be cost-effective is very remote.
With the understanding that, in order to be faced, this challenge needs to include the participation of all in the search for solutions, and by continuing its line of scientific events, Expressa Distribuidora de Medicamentos has put together this whitepaper to discuss access to orphan drugs in Brazil and also new cost-effective approaches to Health Technology Assessment.
Download this whitepaper now to find out more about the challenges of access to orphan drugs in Brazil.
Expressa are joining us this year at the World Orphan Drug Congress USA 2015 to host the cocktail reception on April 23rd. If you are interested in meeting with them to discuss their expertise, then join them at this year’s event.